ATE462428T1 - Behandlung von entzündlichen erkrankungen - Google Patents

Behandlung von entzündlichen erkrankungen

Info

Publication number
ATE462428T1
ATE462428T1 AT04743058T AT04743058T ATE462428T1 AT E462428 T1 ATE462428 T1 AT E462428T1 AT 04743058 T AT04743058 T AT 04743058T AT 04743058 T AT04743058 T AT 04743058T AT E462428 T1 ATE462428 T1 AT E462428T1
Authority
AT
Austria
Prior art keywords
treatment
inflammatory diseases
astaxanthin
carotenoid
dha
Prior art date
Application number
AT04743058T
Other languages
English (en)
Inventor
Diane Clayton
Rebecca Rutter
Original Assignee
Advanced Bionutrition Europ Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Bionutrition Europ Lt filed Critical Advanced Bionutrition Europ Lt
Application granted granted Critical
Publication of ATE462428T1 publication Critical patent/ATE462428T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04743058T 2003-06-23 2004-06-23 Behandlung von entzündlichen erkrankungen ATE462428T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314624.8A GB0314624D0 (en) 2003-06-23 2003-06-23 Inflammatory disease treatment
PCT/GB2004/002707 WO2004112776A2 (en) 2003-06-23 2004-06-23 Inflammatory disease treatment

Publications (1)

Publication Number Publication Date
ATE462428T1 true ATE462428T1 (de) 2010-04-15

Family

ID=27637177

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743058T ATE462428T1 (de) 2003-06-23 2004-06-23 Behandlung von entzündlichen erkrankungen

Country Status (6)

Country Link
US (1) US20100291053A1 (de)
EP (1) EP1635810B1 (de)
AT (1) ATE462428T1 (de)
DE (1) DE602004026303D1 (de)
GB (1) GB0314624D0 (de)
WO (1) WO2004112776A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529055C (en) * 2003-06-19 2013-10-15 Advanced Bionutrition Corp. Improved absorption of fat-soluble nutrients
CA2568009A1 (en) * 2004-05-25 2005-12-08 Pfizer Products Inc. Use of ppar agonists to treat ruminants
JP2006016407A (ja) * 2005-06-15 2006-01-19 Yamaha Motor Co Ltd ホスホジエステラーゼ阻害剤
EP1896077B1 (de) * 2005-06-29 2012-08-15 Hill's Pet Nutrition, Inc. Verfahren und zusammensetzungen zur prävention und behandlung von entzündlichen erkrankungen
JP2007153845A (ja) * 2005-12-07 2007-06-21 Yamaha Motor Co Ltd 脂肪蓄積抑制剤
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US9265745B2 (en) * 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
EP1800675B1 (de) * 2005-12-23 2011-05-18 N.V. Nutricia Zusammensetzung enthaltend mehrfach ungesättigte Fettsäuren, Proteine, Mangan und/oder Molybden und Nukleotide/Nukleoside, zur Behandlung von Demenz
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
JP2009525949A (ja) * 2005-12-29 2009-07-16 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 炎症性腸疾患を予防または治療するための組成物および方法
EP2117354B1 (de) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. Trockenes nahrungsmittel mit lebendem probiotikum
EP1961311A1 (de) * 2007-02-23 2008-08-27 Belovo S.A., Egg Science & Technology Nahrungsmittel, enthaltend mehrfach ungesättigte Fettsäuren, zur Vorbeugung chronischer Erkrankungen
CN101909610B (zh) * 2007-12-28 2013-12-04 尤尼蒂卡株式会社 口服给药组合物
NO20081487L (no) 2008-03-27 2009-09-28 Smartfish As Helsefremmende drikk
AU2009335094B2 (en) 2008-12-30 2012-11-15 Hill's Pet Nutrition, Inc. Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
EP2435554B1 (de) 2009-05-26 2017-07-26 Advanced Bionutrition Corporation Stabile trockenpulverzusammensetzung mit biologisch aktiven mikroorganismen und/oder bioaktiven materialien sowie herstellungsverfahren dafür
NO333013B1 (no) 2009-07-06 2013-02-18 Smartfish As Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
AU2009354456B2 (en) 2009-10-30 2014-05-08 Tharos Ltd Solvent-free process for obtaining phospholipids and neutral enriched krill oils
TWI492744B (zh) * 2009-12-04 2015-07-21 Abbott Lab 使用類胡蘿蔔素調節早產兒發炎症之方法
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
PL2529004T3 (pl) 2010-01-28 2017-12-29 Advanced Bionutrition Corporation Sucha szklista kompozycja zawierająca bioaktywny materiał
US20130137767A1 (en) * 2010-02-02 2013-05-30 Dsm Ip Assets B.V. Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
US20140205627A1 (en) * 2010-04-30 2014-07-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) per-oxidation in humans using algae based oils and astaxanthin
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
JP2013532128A (ja) 2010-05-12 2013-08-15 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 愛玩動物の炎症を抑制および予防し、炎症状態を緩和する方法
GB201009368D0 (en) * 2010-06-04 2010-07-21 Sana Pharma As Dietary formulations
AR082682A1 (es) 2010-08-13 2012-12-26 Advanced Bionutrition Corp Composicion estabilizadora de almacenamiento en seco para materiales biologicos
DE102011052687A1 (de) 2011-08-12 2013-02-14 Lohmann Animal Health Gmbh Verwendung von Antioxidantien
WO2013032333A1 (en) * 2011-09-01 2013-03-07 Algae Biotech S.L. Oral dosage units containing astaxanthin, phospholipids and omega-3 fatty acids
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CA3129309C (en) * 2013-06-13 2023-12-19 Altera International, Ltd. Compositions for improving reproductive and respiratory health of mammals
JP2016523905A (ja) 2013-06-27 2016-08-12 スマートフィッシュ・アーエス 炎症を治療するための魚油及びジュースを含む組成物の使用
US10172915B2 (en) * 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
WO2015142705A1 (en) * 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using algae based oils
DE212015000073U1 (de) * 2014-03-18 2016-12-06 U.S. Nutraceuticals Llc Dba Valensa International Zusammensetzung zum Mildern von Gelenkschmerzen mittels Phopholipiden und Astaxanthin
WO2015142702A1 (en) * 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and roe extract
DE212015000033U1 (de) * 2014-03-19 2016-08-26 U.S. Nutraceuticals, Llc D/B/A Valensa International Therapeutische Astaxanthin- und Phospholipidzusammensetzung
WO2015162246A1 (en) * 2014-04-24 2015-10-29 Dsm Ip Assets B.V. Novel use of a nutraceutical composition in animal feed
WO2015184109A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in adult non-human animals
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
MY194231A (en) 2015-07-29 2022-11-23 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
FR3045069B1 (fr) 2015-12-14 2019-01-25 Metabolium Procede d'enrichissement de protistes en lipides riches en acides gras polyinsatures, plus particulierement de classe omega 3, et sa mise en oeuvre pour la production de ces lipides
CN107126551B (zh) * 2017-05-18 2020-09-01 福州大学 微藻蛋白酶解肽在制备预防及治疗肠炎药物中的应用
JP7355394B2 (ja) * 2018-05-03 2023-10-03 エル．イー．エー．エフ． ホールディングス グループ エルエルシー カロテノイド組成物およびその使用
MX2021001446A (es) * 2018-08-27 2021-03-25 Soc Des Produits Neste S A Composiciones y metodos para el tratamiento de la mastitis.
CN109090248A (zh) * 2018-09-11 2018-12-28 内蒙古伊利实业集团股份有限公司 一种用于预防小儿肺炎疾病的营养组合物
JP7500037B2 (ja) * 2019-07-24 2024-06-17 国立大学法人 東京大学 血中尿酸値低下剤及び血中尿酸値低下用食品組成物
CN114761029A (zh) * 2019-11-29 2022-07-15 雀巢产品有限公司 用于预防或治疗乳腺炎的具有益生菌和n-3脂肪酸的组合物和方法
US20230040010A1 (en) * 2020-01-16 2023-02-09 Societe Des Produits Nestle S.A. Compositions and methods for the treatment of mastitis
WO2021207650A1 (en) * 2020-04-09 2021-10-14 L.E.A.F. Holdings Group Llc Trans-crocetin compositions and treatment regimens
WO2022043287A1 (en) * 2020-08-25 2022-03-03 Dsm Ip Assets B.V. Adonirubin and dha to prevent chronic inflammation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
SE522246C2 (sv) * 1997-02-27 2004-01-27 Astacarotene Ab Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion
US5955102A (en) * 1998-09-04 1999-09-21 Amway Corporation Softgel capsule containing DHA and antioxidants
SE9903619D0 (sv) * 1999-10-07 1999-10-07 Astacarotene Ab Use and method of treatment
CN102319266B (zh) * 2001-06-18 2014-12-17 海王星技术&生物资源有限公司 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
AR039170A1 (es) * 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
US20070082008A1 (en) * 2003-03-07 2007-04-12 Advanced Bionutrition Corporation Feed formulation for terrestrial and aquatic animals
WO2004082366A2 (en) * 2003-03-19 2004-09-30 Regents Of The University Of Minnesota Methods to confer enhanced floral properties to plants

Also Published As

Publication number Publication date
EP1635810B1 (de) 2010-03-31
EP1635810A2 (de) 2006-03-22
WO2004112776A3 (en) 2005-03-31
WO2004112776A2 (en) 2004-12-29
DE602004026303D1 (de) 2010-05-12
GB0314624D0 (en) 2003-07-30
US20100291053A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
ATE462428T1 (de) Behandlung von entzündlichen erkrankungen
ATE291910T1 (de) Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
DE602005019856D1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
IS8233A (is) Própíónsýruafleiður sem eru gagnlegar í meðhöndlun á fitusjúkdómum
NO20074318L (no) Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
WO2005016859A3 (en) Proteasome inhibitors and methods of using the same
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
IL173722A0 (en) Proteasome inhibitors and methods of using the same
CL2012002013A1 (es) Microorganismos aislado thrastochytrium sp. atcc pta-10212 util en la produccion de acidos grasos omega-3
NO20070561L (no) Sammensetninger og fremgangsmater for a behandle oyesykdommer og tilstander.
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
EP2377528A3 (de) Fettsäure-Stoffwechsel-Hemmer zur Verwendung in der Behandlung von Krebs
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
AR039170A1 (es) Co-granulos de dha y romero y metodos de uso
NZ582556A (en) Pharmaceutical composition for treating wounds and related methods
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
MY162518A (en) Proteasome inhibitors and methods of using the same
EA200602002A1 (ru) Применение спинозинов для заживления ран
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
WO2007027476A3 (en) Treating premature ejaculation using gabapentin and pregabalin prodrugs
WO2003080568A3 (en) Probucol derivatives
AR038925A1 (es) Composiciones para el tratamiento del cabello
PA8579401A1 (es) Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b
DE60322983D1 (de) Pflanzliche zusammensetzung zur behandlung von gastrointestinalen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties